Claims 1-35 (Withdrawn)

36. (Currently Amended) A method for treating neoplasm in a mammal, comprising *in situ* administering to neoplasm of a mammal an effective amount of a hapten and coagulation agent(s) ~~or treatment(s)~~ that causes coagulation of the neoplasm, wherein said hapten is trinitrophenol (TNP) and said coagulation agents are a combination of H_2O_2 and ethanol, whereby an ~~autologous~~ immune response is generated against the neoplasm and the neoplasm is treated.

37. (Original) The method of claim 36, wherein the mammal is a human.

Claim 38 (Canceled)

A1

39. (Original) The method of claim 36, further comprising administering to neoplasm a facilitating agent that facilitates conjugation between the hapten and a tumor antigen of the neoplasm.

40. (Original) The method of claim 39, wherein the facilitating agent is a chelator or a chemical linking agent.

Claim 41 (Canceled)

42. (Original) The method of claim 40, wherein the chemical linking agent is carbodiimide.

43. (Original) The method of claim 36, further comprising administering an immune response potentiator to the neoplasm.

44. (Original) The method of claim 43, wherein the immune response potentiator is selected from the group consisting of Bacille Calmette-Guerin (BCG), Corynebacterium Parvum, Brucella abortus extract, glucan, levamisole, tilorone, an enzyme, a non-virulent virus, a polysaccharide and a herb extract.

Claims 45 and 46 (Withdrawn)

47. (Original) The method of claim 36, further comprising administering a coagulation lysing agent to the neoplasm.

48. (Original) The method of claim 47, wherein the coagulation lysing agent is selected from the group consisting of proteinase K, Glycosyl-phosphatidylinositol-B7 and pancreatin.

Claim 49 (Canceled)

50. (Currently Amended) The method of claim 4936, wherein the ~~oxidizing or reducing agent, the protein denaturing agent and the hapten~~ TNP, H_2O_2 and ethanol are formulated in a single pharmaceutical composition or each is formulated in a separate pharmaceutical composition.

Claims 51 and 52 (Canceled)

Claim 53 (Withdrawn)

Claims 54-56 (Canceled)

57. (Currently Amended) The method of claim 49, ~~wherein the combination further comprises an anti-neoplasm agent~~ further comprising administering AraC to the mammal.

Claims 58-68 (Canceled)

69. (Currently Amended) The method of claim ~~49~~36, wherein the ~~oxidizing agent or reducing agent~~ H_2O_2 is from about 0.01% (w/w) to about 35% (w/w), the ~~protein denaturing agent~~ ethanol is from about 1% (w/w) to about 99% (w/w) and the ~~hapten~~ TNP is from about 1 mg/ml to about 80 mg/ml.

Claim 70 (Canceled)

71. (Original) The method of claim 36, wherein the autologous immune response generated by the combined action of the hapten and the coagulation agent or treatment comprises or is a humoral and/or cellular immune response.

72. (Original) The method of claim 36, wherein the neoplasm to be treated is selected from the group consisting of adrenal gland, anus, auditory nerve, bile ducts, bladder, bone, brain, breast, bruccal, central nervous system, cervix, colon, ear, endometrium, esophagus, eye, eyelids, fallopian tube, gastrointestinal tract, head and neck, heart, kidney, larynx, liver, lung, mandible, mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity, ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland, rectum, retina, salivary glands, skin, small intestine, spinal cord, stomach, testes, thyroid, tonsil, urethra, uterus, vagina, vestibulocochlear nerve and vulva neoplasm.

73. (Original) The method of claim 36, wherein the neoplasm to be treated is a solid tumor.

74. (Original) The method of claim 73, wherein the size of the solid tumor is larger than 10^8 cells.

75. (Original) The method of claim 74, wherein the size of the solid tumor is from about $5X10^9$ to about 10^{11} cells.

76. (Original) The method of claim 36, wherein the hapten and the coagulation agent(s) are administered to the neoplasm via injection.

77. (Original) The method of claim 36, wherein the hapten and the coagulation agent(s) are administered to the neoplasm in combination with a surgical procedure.

Claim 78 (Withdrawn)

79. (Original) The method of claim 36, further comprising *in situ* administering a molecule selected from the group consisting of a suicide gene sequence, a cytolytic gene sequence, a cytokine gene sequence, a radiation sensitizer, a cytokine-containing depot, a reporter and a reporter gene sequence.

REMARKS

Upon entry of the present Amendment, claims 36, 37, 39, 40, 42-44, 47, 48, 50, 57, 69, 71-77 and 79 will be pending. Claims 1-35, 38, 41, 45, 46, 49, 51-56, 58-68, 70 and 78 are withdrawn from consideration and/or canceled. Applicant reserves the rights to pursue the withdrawn and/or canceled subject matter in a subsequent application. Support for amended